Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Chemical Allergen [EPC]
Imidurea (Imidazolidinyl Urea) is a non-standardized chemical allergen and antimicrobial preservative used primarily in diagnostic patch testing and as a stabilizing agent in topical formulations.
Name
Imidurea
Raw Name
IMIDUREA
Category
Non-Standardized Chemical Allergen [EPC]
Drug Count
5
Variant Count
5
Last Verified
February 17, 2026
About Imidurea
Imidurea (Imidazolidinyl Urea) is a non-standardized chemical allergen and antimicrobial preservative used primarily in diagnostic patch testing and as a stabilizing agent in topical formulations.
Detailed information about Imidurea
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Imidurea.
Belonging to a class of compounds known as formaldehyde releasers, Imidurea is synthesized through the reaction of allantoin and formaldehyde. Despite its name, it is not a single discrete molecule but rather a mixture of various condensation products. Its primary function in topical medications, lotions, shampoos, and ointments is to prevent the growth of Gram-positive and Gram-negative bacteria, as well as certain molds and yeasts. This preservation is vital for maintaining the shelf-life and safety of aqueous-based products.
From a clinical standpoint, Imidurea is a 'pro-hapten.' A hapten is a small molecule that, while not antigenic on its own, can elicit an immune response when it binds to a larger protein carrier. Imidurea achieves this by slowly releasing small amounts of formaldehyde, which then reacts with skin proteins to form an allergen. The FDA has approved its use in standardized patch test kits, such as the T.R.U.E. TEST (Thin-layer Rapid Use Epicutaneous Test), which is the gold standard for diagnosing skin allergies in the United States and Europe.
The mechanism of action for Imidurea varies depending on whether it is being viewed as a preservative or a diagnostic allergen. At the molecular level, its antimicrobial activity is derived from its ability to act as a formaldehyde reservoir. In aqueous environments, the chemical bonds within the imidazolidinyl structure undergo slow hydrolysis, releasing formaldehyde (CH2O). Formaldehyde is a highly reactive molecule that cross-links proteins and nucleic acids within microbial cells, effectively neutralizing their ability to replicate or maintain cellular integrity.
In the context of the Mechanism of Action (MoA) provided—Ammonium Ion Binding Activity and Methylating Activity—Imidurea exhibits unique biochemical properties. As a nitrogen-binding agent, it can interact with ammonium ions, which is a property explored in specific chemical synthesis and potential metabolic research. Its methylating activity refers to its capacity to donate methyl groups or participate in methylene bridge formation, a process critical in the denaturation of microbial proteins.
When used for diagnostic purposes, the mechanism shifts to the induction of a Type IV (delayed-type) hypersensitivity reaction. When a healthcare provider applies a patch containing Imidurea to a patient's skin, the released formaldehyde or the Imidurea molecule itself penetrates the stratum corneum (the outermost layer of the skin). There, it binds to epidermal proteins. This complex is then processed by Langerhans cells (specialized immune cells in the skin), which migrate to local lymph nodes and present the antigen to T-lymphocytes. If the patient has been previously sensitized, these T-cells will migrate back to the site of application, causing the characteristic redness, swelling, and itching associated with a positive test result.
Because Imidurea is almost exclusively applied topically or used in diagnostic patches, its systemic pharmacokinetic profile differs significantly from oral or intravenous medications.
Imidurea is utilized in several distinct clinical and commercial capacities:
Imidurea is not available as an oral tablet or systemic injection. Its forms include:
> Important: Only your healthcare provider can determine if Imidurea is right for your specific condition or if you require testing for Imidurea sensitivity.
In clinical practice, the 'dosage' of Imidurea refers to its concentration in diagnostic tests or its percentage as a preservative in topical products.
Imidurea is approved for use in pediatric patients undergoing diagnostic patch testing, typically for children aged 6 years and older. The concentration used is generally the same as the adult dose (2.0% in petrolatum), although some clinicians may opt for a lower concentration (1.0%) in children with exceptionally sensitive or thin skin.
> Note: Safety and efficacy in infants under 12 months of age have not been extensively established for diagnostic purposes. Use in this population must be guided by a pediatric allergist or dermatologist.
Because Imidurea is applied topically and systemic absorption is minimal, no dosage adjustments are typically required for patients with renal impairment. However, clinicians should monitor for potential skin sensitivity changes in patients with end-stage renal disease (ESRD), as uremia can alter skin barrier function.
There are no specific dosage adjustments required for patients with liver disease. The metabolic load of processing the trace amounts of formaldehyde released by Imidurea is well within the capacity of even a compromised liver.
In geriatric patients, the skin is often thinner and less hydrated (asteatotic). While the standard 2.0% concentration is used, the healthcare provider may observe a higher rate of irritant reactions. Careful interpretation of patch test results is necessary to distinguish between true allergy and simple irritation.
Imidurea is not 'taken' in the traditional sense; it is applied to the skin.
Diagnostic kits containing Imidurea should be stored in a refrigerator (2°C to 8°C or 36°F to 46°F) to prevent the premature degradation of the compound and the excessive release of formaldehyde within the packaging.
In the context of patch testing, a 'missed dose' occurs if a patch falls off prematurely. If the patch is removed or falls off before the 48-hour mark, the test results may be inconclusive. Patients should contact their clinic immediately to determine if the patch needs to be reapplied or if the test must be restarted.
Systemic overdose of Imidurea via topical application is virtually impossible. However, localized 'overdose' can occur if a product with an excessively high concentration is used.
> Important: Follow your healthcare provider's dosing and application instructions. Do not apply Imidurea-containing diagnostic materials yourself without medical guidance.
When Imidurea is used for diagnostic patch testing, side effects are expected, as the goal is to elicit a reaction in sensitized individuals.
While extremely rare, systemic reactions can occur during skin testing.
> Warning: Stop using any product containing Imidurea and call your doctor immediately if you experience any of these:
No FDA black box warnings exist for Imidurea. It is generally recognized as safe (GRAS) for its intended use as a preservative and is a standard diagnostic tool with a well-established safety profile. However, its potential as a sensitizer is the reason for its inclusion in allergen panels.
Report any unusual symptoms or persistent skin changes to your healthcare provider. If you suspect you are having an allergic reaction to a cosmetic or medication, keep the product packaging to show your doctor.
Imidurea is a known contact allergen. Patients with a history of 'sensitive skin' or frequent reactions to cosmetics should be particularly cautious. It is essential to understand that Imidurea is a formaldehyde releaser. This means that if you are allergic to formaldehyde, you will almost certainly react to Imidurea. Conversely, an allergy to Imidurea may also mean you need to avoid other releasers like Quaternium-15, Diazolidinyl Urea, and DMDM Hydantoin.
There are currently no FDA black box warnings for Imidurea. Unlike systemic drugs with high toxicity profiles, Imidurea's risks are primarily dermatological and localized.
When undergoing diagnostic testing with Imidurea, the following monitoring is required:
Imidurea does not have any systemic sedative effects and does not impair the ability to drive or operate machinery. The only restriction is physical: the patches on the back may slightly limit range of motion or cause discomfort while sitting against a chair.
There are no known direct interactions between alcohol consumption and topical Imidurea application. However, alcohol can cause vasodilation (widening of blood vessels), which might theoretically increase the itchiness or redness of an active patch test site.
If Imidurea is being used as a preservative in a medication you are using, and you develop a rash, you must discontinue the product immediately. Unlike some systemic medications, there is no 'tapering' required for topical products containing Imidurea. Stopping the product is the primary treatment for the resulting contact dermatitis.
> Important: Discuss all your medical conditions, including any history of asthma or severe allergies, with your healthcare provider before starting Imidurea testing.
There are no systemic drugs that are strictly contraindicated with the topical use of Imidurea. However, in the context of diagnostic accuracy, certain combinations are contraindicated:
There are no known food interactions with Imidurea. Unlike some allergens (like balsam of Peru), there is no evidence that a 'low-formaldehyde diet' is necessary or effective for patients allergic to Imidurea.
Imidurea does not interfere with standard blood tests, urinalysis, or imaging (X-rays/MRIs). Its only 'interaction' is with the patch test itself, where it is the active agent being measured.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any that affect your immune system or skin health.
Imidurea must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients who are sensitive to Imidurea are highly likely to show cross-sensitivity to:
These chemicals are structurally related or share the same mechanism of formaldehyde release. If you are diagnosed with an Imidurea allergy, your doctor will likely advise you to avoid this entire group of preservatives.
> Important: Your healthcare provider will evaluate your complete medical history and current skin condition before prescribing or administering Imidurea for testing.
Imidurea is used topically and in very small quantities during diagnostic testing. However, there is a lack of controlled data regarding its use in pregnant women. Formaldehyde, its primary metabolite, is produced endogenously in the human body, but exogenous exposure during pregnancy should be minimized. Most clinical guidelines recommend postponing elective patch testing with Imidurea until the postpartum period. If exposure occurs via a cosmetic product, the risk to the fetus is considered negligible due to minimal systemic absorption.
It is unknown if Imidurea or its metabolites are excreted in human milk. However, given the low systemic absorption from topical application, it is highly unlikely that clinically significant amounts would reach a nursing infant. Caution should be exercised to ensure that the infant does not come into direct skin-to-skin contact with a site where an Imidurea patch was recently applied or where a product containing Imidurea was used (e.g., on the mother's breast).
Imidurea is a common cause of contact dermatitis in children, often due to its presence in wipes, soaps, and shampoos.
In patients over 65, the skin's immune response may be slightly delayed or diminished (immunosenescence). This can lead to 'weak' positive reactions that are difficult to interpret. Additionally, elderly patients are more likely to be on multiple systemic medications (polypharmacy) that could interfere with skin testing. Healthcare providers should also consider the risk of skin tears from the adhesive tape used to secure Imidurea patches in this population.
No specific studies have been conducted in patients with renal impairment. However, because the primary route of elimination for absorbed formaldehyde/formate is renal, theoretically, extremely high levels of exposure could lead to accumulation. In the context of standard cosmetic use or a 48-hour patch test, this is not a clinical concern.
As the liver is the primary site for the oxidation of formaldehyde to formate, severe hepatic failure could theoretically slow the metabolism of absorbed Imidurea components. However, the amounts used in dermatology are so small that hepatic impairment is not considered a contraindication or a reason for dose adjustment.
> Important: Special populations require individualized medical assessment. Always inform your specialist about your pregnancy status or any chronic organ conditions.
Imidurea functions primarily as a formaldehyde releaser. Its antimicrobial efficacy is due to the slow, continuous release of formaldehyde into the aqueous phase of a product. Formaldehyde acts as an alkylating agent, reacting with the amino and sulfhydryl groups of microbial proteins and the nitrogenous bases of nucleic acids. This disrupts the cell membrane and inhibits essential enzymatic processes within bacteria and fungi.
In the context of its classification as a Nitrogen Binding Agent [EPC], Imidurea's molecular structure allows it to interact with ammonium ions, potentially acting as a sequestering agent in specific biochemical environments. Its Methylating Activity [MoA] refers to the transfer of a hydroxymethyl group to various substrates, a key step in the cross-linking of proteins that characterizes both its preservative action and its role as a hapten in allergic reactions.
| Parameter | Value |
|---|---|
| Bioavailability | Negligible (<1% systemic) |
| Protein Binding | High (binds to epidermal keratin and serum albumin) |
| Half-life | ~2-4 hours (for released formaldehyde in tissue) |
| Tmax | 48-72 hours (for peak immunological reaction) |
| Metabolism | Non-enzymatic hydrolysis; further oxidation by formaldehyde dehydrogenase |
| Excretion | Renal (as formate); Pulmonary (as CO2) |
Imidurea is classified as a Non-Standardized Chemical Allergen [EPC]. It belongs to the broader category of Formaldehyde-Releasing Preservatives (FRPs). In the therapeutic hierarchy, it is grouped with other diagnostic allergens used in epicutaneous testing to identify the cause of contact dermatitis.
Common questions about Imidurea
Imidurea is primarily used as an antimicrobial preservative in cosmetics, lotions, and topical medications to prevent the growth of bacteria and mold. In a clinical setting, it is used as a diagnostic allergen in patch tests to determine if a patient has a contact allergy to formaldehyde-releasing chemicals. By applying a small, controlled amount to the skin, doctors can identify if this substance is the cause of a patient's rash or eczema. It is one of the most common preservatives found in 'wash-off' and 'leave-on' skin products. If you are diagnosed with an allergy to it, you must avoid products that list it on the label.
The most common side effects occur during diagnostic patch testing and include redness, itching, and mild swelling at the site where the patch was applied. These symptoms are actually the 'positive' signs that the test is working to identify an allergy. Some people may also experience a mild 'irritant' reaction, which is a non-allergic skin irritation that disappears quickly after the patch is removed. In more sensitive individuals, small blisters may form at the test site. Systemic side effects like headache or nausea are extremely rare because the drug is not absorbed into the bloodstream in significant amounts. Always report persistent or spreading rashes to your dermatologist.
There is no known direct interaction between alcohol and the topical use of Imidurea. Because Imidurea is not taken orally and very little enters the bloodstream, alcohol does not affect how the drug is metabolized. However, if you are undergoing patch testing, alcohol can cause skin flushing and increased blood flow to the skin, which might make a positive test site feel itchier or more inflamed. It is generally fine to drink in moderation, but you should avoid excessive alcohol that might lead to accidental removal of the test patches. Always follow the specific lifestyle restrictions provided by your allergist during the testing window.
Imidurea is generally considered to have low risk during pregnancy because it is applied topically and systemic absorption is minimal. However, most healthcare providers recommend avoiding elective diagnostic patch testing while pregnant to prevent any unnecessary immune system stimulation. There are no well-controlled studies on Imidurea in pregnant women, so it is usually categorized as 'use only if clearly needed.' If you discover Imidurea in your daily moisturizer while pregnant, there is likely no cause for alarm, but you should discuss it with your obstetrician. Postponing diagnostic tests until after delivery is the standard cautious approach.
The 'onset' of Imidurea depends on its use. As a preservative in your skincare products, it works immediately and continuously to keep the product free of germs. In a diagnostic patch test, it takes time for your immune system to respond. A preliminary reading is usually done 48 hours after the patch is applied, but many people do not show a reaction until 72 or 96 hours (3 to 4 days) after the initial application. This is why it is called a 'delayed-type' hypersensitivity reaction. You must attend all follow-up appointments to ensure the results are read correctly by your doctor.
Yes, you can stop using products containing Imidurea at any time without experiencing withdrawal symptoms. Since it is a topical preservative and not a systemic medication like a blood pressure pill or an antidepressant, your body does not develop a dependence on it. In fact, if you are allergic to Imidurea, the primary treatment is to stop using all products containing it immediately. Once you stop exposure, your skin will typically begin to heal within a few days to a week. If you are using a prescription cream that contains Imidurea as a preservative, consult your doctor for a 'preservative-free' alternative before stopping.
In the context of patch testing, a 'missed dose' means the patch has fallen off or was removed too early. If this happens, do not try to tape it back on yourself with household tape, as this can irritate the skin and ruin the test. Instead, contact your doctor's office immediately. They will decide if the patch can be reapplied or if you need to wait and restart the test at a later date. If you miss your appointment to have the patches read, the results may become invalid, as the timing of the reading is critical for distinguishing between an allergy and a simple irritation.
No, Imidurea does not cause weight gain. Weight gain is typically a side effect of systemic medications that affect metabolism, hormones, or appetite, such as oral steroids or certain antidepressants. Because Imidurea is used only on the skin and is not absorbed into the body in significant amounts, it has no effect on your metabolic rate, fat storage, or hunger levels. Any changes in weight while using a product containing Imidurea are likely due to other factors, such as diet, exercise, or other medications you may be taking. If you have concerns about weight changes, discuss them with your primary care physician.
Imidurea can generally be used while you are taking other medications, but some drugs can interfere with diagnostic testing. If you are taking oral steroids (like prednisone) or other drugs that suppress the immune system, they may 'hide' an allergy to Imidurea, leading to a false-negative patch test. You should inform your dermatologist about all medications you are taking before the test begins. Topical medications applied directly to the test site, such as steroid creams, must also be avoided. Most other common medications, like those for heart disease, diabetes, or birth control, do not interact with Imidurea.
Imidurea itself is a chemical ingredient rather than a brand-name drug. It is found in both brand-name and generic topical products, ranging from expensive designer cosmetics to 'store-brand' lotions and prescription generic creams. When used for allergy testing, it is part of standardized kits produced by various laboratory manufacturers. There is no 'brand-name' version of Imidurea that is considered superior to a generic version; the chemical structure is the same regardless of the manufacturer. If you are allergic, you must check the 'Ingredients' or 'Inactive Ingredients' list on every product, regardless of whether it is a brand name or generic.